Forward Therapeutics Achieves Phase 1 Completion for FT2109, Advancing Oral TNF Inhibitor to Phase 2

The completion of Phase 1 trials for Forward Therapeutics' oral TNF signaling inhibitors FT2109 and FT751 signals a formulation shift that CMOs and fill-finish operators should begin factoring into capacity planning now. With FT2109 selected as the lead candidate for Phase 2, the program represents a direct challenge to the injectable anti-TNF biologic category that has defined inflammation manufacturing demands for two decades.

FT2109 is a small molecule designed to inhibit TNFR1 signaling by selectively binding soluble TNF, sparing membrane TNF pathways associated with host defense. That mechanistic specificity distinguishes it from broad-spectrum biologic blockers and, from a manufacturing standpoint, moves the product class from sterile injectable fill-finish into oral solid dose or liquid formulation infrastructure. Both Phase 1 programs demonstrated acceptable safety and pharmacologic profiles; the company cited FT2109's overall profile as the basis for lead selection over FT751.

For contract manufacturers currently aligned to biologic anti-TNF production, the trajectory of next-generation oral TNFsi programs warrants attention at the capacity-planning level. Oral small molecule scale-up operates under 21 CFR Part 211 solid-dose GMP requirements rather than the aseptic processing and sterility assurance controls governing injectable biologics. Process validation strategies, equipment qualification, and environmental monitoring programs differ materially across these modalities, and organizations that have not maintained oral dose capabilities alongside biologic suites may face lead-time constraints as Phase 2 and eventual Phase 3 demand materializes.

Forward Therapeutics developed both candidates through its SWIFT platform, a proprietary discovery engine combining curated compound libraries with structural screening. The internally discovered origin of both assets means no licensing or co-development manufacturing obligations are currently disclosed, leaving CMO selection for Phase 2 supply an open variable. Phase 1 data for FT2109 are expected to be submitted for presentation at a future scientific conference, which will provide the first public pharmacokinetic and safety dataset for external technical review.

The Phase 2 program design, target indication, and anticipated enrollment timeline have not yet been disclosed, making site qualification and batch record preparation the near-term operational checkpoint for any manufacturing partner entering discussions with the company.

Source: Forward Therapeutics via GlobeNewswire, 14 May 2026.